Experimental drug triapine tested in rare uterine cancer before surgery
NCT ID NCT04494113
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing the drug triapine in 12 women with a rare and aggressive type of uterine cancer called uterine serous adenocarcinoma. Participants receive a single dose of triapine before their scheduled hysterectomy, and researchers analyze tissue samples to see how the drug affects cancer cells. The goal is to understand if triapine can slow tumor growth, not yet to prove it works as a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Triapine (a drug given intravenously that may block enzymes needed for cancer cell growth)
What this could lead to
If successful, this could point toward a new treatment option for uterine serous adenocarcinoma, a rare and aggressive cancer.
What could go wrong
This is a very early (phase 0) trial with only 12 participants, so results are preliminary and may not lead to a proven treatment. The drug may also cause side effects like low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146, United States
-
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442, United States
-
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, 33324, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States